Loading stock data…
Nuvectis Pharma (NVCT)
$28.21+1.02 (+3.75%)
Market OpenUpdated 3:11 PM EDT
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Nuvectis Pharma, Inc. in the Healthcare sector is trading at $28.21 with a market capitalization of $305M. Wall Street consensus targets $29.20 (5 analysts), implying a +3.5% move over the next 12 months. The stock is currently near its 52-week high of $29.27, remaining 231.5% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$6.26M↑ | -$7.62M↑ | -$7.79M↓ | -$6.59M↓ | -$5.57M |
| Net Income | -$6.05M↑ | -$7.31M↑ | -$7.46M↓ | -$6.33M↓ | -$5.33M |
Peer Comparison
JNJUNHPFE
Fundamentals
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug ca...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$304.51M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-191.00%
Volume
Today's trading volume
283,992
Recent News
What Makes Nuvectis Pharma (NVCT) a New Buy Stock
Nuvectis Pharma (NVCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Haisco and Nuvectis sign licensing deal for two drugs
Haisco will receive $40m upfront and may earn up to $1.4bn in additional milestone payments.
Nuvectis Expands Pipeline with Haisco Licensing Agreement for Two Clinical-Stage Drug Candidates (NVCT)
Nuvectis Pharma Inc (NASDAQ:NVCT) shares gained 5. 7% in premarket trading on Monday after the company announced a licensing agreement with Haisco Pharmaceutical Group that grants it exclusive rights outside China to two late-stage clinical assets.
Wall Street Analysts Think Nuvectis Pharma (NVCT) Could Surge 57%: Read This Before Placing a Bet
The mean of analysts' price targets for Nuvectis Pharma (NVCT) points to a 57% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 62.5% in Nuvectis Pharma (NVCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.